Literature DB >> 27958709

Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design.

Major Gooyit1, Pedro O Miranda1, Cody J Wenthur1, Alex Ducime1, Kim D Janda1.   

Abstract

Active vaccination examining a single hapten engendered with a series of peptidic linkers has resulted in the production of antimethamphetamine antibodies. Given the limited chemical complexity of methamphetamine, the structure of the linker species embedded within the hapten could have a substantial effect on the ultimate efficacy of the resulting vaccines. Herein, we investigate linker effects by generating a series of methamphetamine haptens that harbor a linker with varying amino acid identity, peptide length, and associated carrier protein. Independent changes in each of these parameters were found to result in alterations in both the quantity and quality of the antibodies induced by vaccination. Although it was found that the consequence of the linker design was also dependent on the identity of the carrier protein, we demonstrate overall that the inclusion of a short, structurally simple, amino acid linker benefits the efficacy of a methamphetamine vaccine in limiting brain penetration of the free drug.

Entities:  

Keywords:  CNS distribution; Methamphetamine; antimethamphetamine antibody; hapten; linker design; vaccine

Mesh:

Substances:

Year:  2016        PMID: 27958709      PMCID: PMC5711417          DOI: 10.1021/acschemneuro.6b00389

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  31 in total

Review 1.  A review of the clinical pharmacology of methamphetamine.

Authors:  Christopher C Cruickshank; Kyle R Dyer
Journal:  Addiction       Date:  2009-04-29       Impact factor: 6.526

2.  The new danger of synthetic drugs.

Authors:  Carrie Arnold
Journal:  Lancet       Date:  2013-07-06       Impact factor: 79.321

3.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

Review 4.  Neurologic manifestations of chronic methamphetamine abuse.

Authors:  Daniel E Rusyniak
Journal:  Neurol Clin       Date:  2011-06-24       Impact factor: 3.806

Review 5.  Methamphetamine: history, pathophysiology, adverse health effects, current trends, and hazards associated with the clandestine manufacture of methamphetamine.

Authors:  David Vearrier; Michael I Greenberg; Susan Ney Miller; Jolene T Okaneku; David A Haggerty
Journal:  Dis Mon       Date:  2012-02       Impact factor: 3.800

6.  Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens.

Authors:  Marco Pravetoni; Morgan Le Naour; Ashli M Tucker; Theresa M Harmon; Tara M Hawley; Philip S Portoghese; Paul R Pentel
Journal:  J Med Chem       Date:  2013-01-15       Impact factor: 7.446

Review 7.  The methamphetamine problem in the United States.

Authors:  Rachel Gonzales; Larissa Mooney; Richard A Rawson
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

8.  Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES).

Authors:  Rebecca McKetin; Jake M Najman; Amanda L Baker; Dan I Lubman; Sharon Dawe; Robert Ali; Nicole K Lee; Richard P Mattick; Abdullah Mamun
Journal:  Addiction       Date:  2012-07-12       Impact factor: 6.526

9.  Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.

Authors:  Sarah J White; Howard P Hendrickson; William T Atchley; Elizabeth M Laurenzana; W Brooks Gentry; D Keith Williams; S Michael Owens
Journal:  Drug Metab Dispos       Date:  2014-05-19       Impact factor: 3.922

10.  Investigating hapten clustering as a strategy to enhance vaccines against drugs of abuse.

Authors:  Karen C Collins; Kim D Janda
Journal:  Bioconjug Chem       Date:  2014-02-25       Impact factor: 4.774

View more
  13 in total

1.  Investigations into the efficacy of multi-component cocaine vaccines.

Authors:  Atsushi Kimishima; Margaret E Olson; Kim D Janda
Journal:  Bioorg Med Chem Lett       Date:  2017-12-20       Impact factor: 2.823

2.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

Review 3.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

4.  Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality.

Authors:  Candy S Hwang; Paul T Bremer; Cody J Wenthur; Sam On Ho; SuMing Chiang; Beverly Ellis; Bin Zhou; Gary Fujii; Kim D Janda
Journal:  Mol Pharm       Date:  2018-02-19       Impact factor: 4.939

5.  Molecular Containers Bind Drugs of Abuse in Vitro and Reverse the Hyperlocomotive Effect of Methamphetamine in Rats.

Authors:  Shweta Ganapati; Stephanie D Grabitz; Steven Murkli; Flora Scheffenbichler; Maíra I Rudolph; Peter Y Zavalij; Matthias Eikermann; Lyle Isaacs
Journal:  Chembiochem       Date:  2017-07-12       Impact factor: 3.164

6.  In Vitro and In Vivo Sequestration of Methamphetamine by a Sulfated Acyclic CB[n]-Type Receptor.

Authors:  Adam T Brockett; Chunlin Deng; Michael Shuster; Suvenika Perera; Delaney DiMaggio; Ming Cheng; Steven Murkli; Volker Briken; Matthew R Roesch; Lyle Isaacs
Journal:  Chemistry       Date:  2021-10-27       Impact factor: 5.236

7.  Efficacious Vaccine against Heroin Contaminated with Fentanyl.

Authors:  Candy S Hwang; Lauren C Smith; Yoshihiro Natori; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2018-03-23       Impact factor: 4.418

8.  Development of a Clinically Viable Heroin Vaccine.

Authors:  Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-06-20       Impact factor: 15.419

9.  Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.

Authors:  Misty W Stevens; Daniela Rüedi-Bettschen; Melinda G Gunnell; Rachel Tawney; C Michael West; S Michael Owens
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.492

10.  In Vitro and In Vivo Sequestration of Phencyclidine by Me4 Cucurbit[8]uril*.

Authors:  Steven Murkli; Jared Klemm; Adam T Brockett; Michael Shuster; Volker Briken; Matthew R Roesch; Lyle Isaacs
Journal:  Chemistry       Date:  2021-01-19       Impact factor: 5.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.